文献速递临床试验与 GCP基础与转化研究流行病学与生物统计

植物性饮食对结直肠癌患者FOLFOX化疗所致胃肠毒性的疗效:多中心分层随机对照试验研究方案

Efficacy of a plant-based diet on FOLFOX chemotherapy-induced gastrointestinal toxicity in patients with colorectal cancer: study protocol for a multicentre, stratified, randomised controlled trial.
PubMed 文献 · Trials · 2026-03-03

本研究为多中心、分层、三臂、平行组、评估者盲、优效性随机对照试验,计划纳入114例18-65岁病理确诊结直肠癌且接受或计划接受FOLFOX化疗的成人,按研究中心和性别分层后1:1:1随机分为结构化植物性饮食策略组、常规饮食指导组、常规饮食指导联合肿瘤全营养配方组,干预6周。主要结局为随访期间CTCAE≥2级胃肠道毒性发生率、血清炎症生物标志物和粪便谱分析。

要点

  • 结构化植物性饮食策略可能减轻FOLFOX化疗相关胃肠毒性。
  • 主要结局包括CTCAE≥2级胃肠毒性发生率、炎症标志物和粪便谱。
  • 探索性整合临床、生物标志物和粪便多组学数据。

核心结论

  • 该试验将评估结构化植物性饮食策略减少化疗所致胃肠毒性及改善相关生物学和患者中心结局的疗效与安全性。

研究设计与样本

  • 多中心、分层、三臂、平行组、评估者盲、优效性随机对照试验。
  • 计划纳入114例18-65岁病理确诊结直肠癌且接受或计划接受FOLFOX化疗的成人。
  • 在中国成都两家医院开展,按研究中心和性别分层后1:1:1随机分组。
  • 干预包括结构化植物性饮食策略、常规饮食指导、常规饮食指导联合肿瘤全营养配方,为期6周。
  • 主要分析遵循意向性治疗原则。

关键数值与推荐

  • 主要结局为随访期间CTCAE≥2级预设胃肠道毒性发生率、血清炎症生物标志物和粪便谱分析。
  • 次要结局包括膳食摄入与饮食质量、生物电阻抗分析体成分、常规临床实验室指标、疲劳、焦虑/抑郁、体力活动和不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gastrointestinal toxicity during FOLFOX chemotherapy for colorectal cancer (CRC) is frequent and can impair oral intake, quality of life, and planned chemotherapy delivery. Safe and scalable dietary strategies are needed as adjuncts to standard supportive care. This trial will evaluate whether a structured plant-based dietary strategy reduces chemotherapy-induced gastrointestinal toxicity (CIGT) and improves related biological and patient-centered outcomes. METHODS: This multicentre, stratified, three-arm, parallel-group, assessor-blinded, superiority randomised controlled trial will enrol 114 adults (18-65 years) with pathologically confirmed CRC receiving (or scheduled to receive) FOLFOX chemotherapy at two hospitals in Chengdu, China. Participants will be randomised (1:1:1), stratified by study site and sex, to (1) a structured plant-based dietary strategy, (2) conventional dietary guidance, or (3) conventional dietary guidance plus an oncology complete nutritional formula, for 6 weeks. Assessments will be performed at baseline and at prespecified time points through week 6. Primary outcomes are (i) the participant-level incidence of any prespecified CTCAE gastrointestinal toxicity of grade ≥ 2 during follow-up, (ii) serum inflammatory biomarkers, and (iii) stool-based profiling. Secondary outcomes include dietary intake and diet quality, body composition by bioelectrical impedance analysis, routine clinical laboratory indices, fatigue, anxiety/depression, physical activity, and adverse events. Primary analyses will follow the intention-to-treat principle. DISCUSSION: This trial will provide evidence on the efficacy and safety of a plant-based dietary strategy to mitigate CIGT during FOLFOX chemotherapy. Integrated clinical, biomarker, and stool multi-omics measures may also support exploration of biological correlates of symptom burden and treatment tolerance. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR), ChiCTR2500095215; registered 03 January 2025. https://www.chictr.org.cn/showproj.html?proj=254099 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Peng W, Shi H, Fan L, et al. Efficacy of a plant-based diet on FOLFOX chemotherapy-induced gastrointestinal toxicity in patients with colorectal cancer: study protocol for a multicentre, stratified, randomised controlled trial. Trials. 2026. PMID: 41772652. doi:10.1186/s13063-026-09573-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。